Zusammenfassung
Die Alzheimer’sche Krankheit (AD), zuerst beschrieben 1907 durch Alois Alzheimer, ist eine neurodegenerative Erkrankung, deren Ursache noch unbekannt ist und für die bis heute keine kausale Therapie existiert. Postmortale und moderne nicht-invasive bildgebende Verfahren liefern Hinweise, daβ im Gehirn von Alzheimer Patienten die Funktion vieler Neurotransmittersysteme durch die Krankheit gestört ist, wobei das cholinerge System besonders stark betroffen ist. Der Verlust cholinerger Neurone tritt auch frühzeitiger auf als derjenige anderer Transmittersysteme. Aus postmortem Untersuchungen an AD-Gehirnen wissen wir, daβ die Verminderung der Aktivität der Cholinacetyltransferase (ChAT), das für die Synthese von Acetylcholin (ACh) verantwortliche Enzym, mit dem Ausmaβ der kognitiven Störungen dieser Patienten korreliert. Diese Befunde sind die Basis der „Cholinergen Hypothese“, auf Grund derer verschiedene therapeutische Ansätze versucht wurden, nämlich die verminderte cholinerge Aktivität zu stimulieren und/oder zu erhalten.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Enz A, Floersheim P (1996) Cholinesterase inhibitors: an overview of their mechanisms of action. In: Giacobini E, Becker R (eds) Alzheimer’s disease: from molecular biology to therapy. Birkhäuser, Boston, pp 211–215
Enz A, Hofmann A, Gmelin G, Kelly PH (1989) Pharmacological properties of the preferentially centrally acting acetylcholinesterase inhibitor SD2 ENA 713. In: Kewitz H, Thomsen T, Bickel U (eds) Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). Zuckschwerdt, München, pp 271–277
Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowsky J (1993) Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. In: Cuello AC (ed) Colinergic function and dysfunction. Elsevier, Amsterdam, pp 431–438 (Prog Brain Res 98)
Karczmar A (1978) Exploitable aspects of cholinergic functions, particularly with respect to the EEG, motor, analgesic and mental functions. In: Jenden D, Hanin I (eds) Cholinergic mechanism and psychopharmacology. Plenum Press, New York, pp 679–708
Massoulie J, Pezzementi L, Bon S, Krejci E, Vallette FR (1993) Molecular and cellular biology of cholinesterases. Prog Neurobiol 41: 31–91 The molecular forms of Cholinesterase and acetylcholinesterase in vertebrates. Ann Rev Neurosci 5: 57–106
Niigawa H, Tanimukai S, Takeda M, Hariguchi S, Nishimura T (1995) Effects of SDZ ENA 713, a novel acetylcholinesterase inhibitor, on learning of rats with basal forebrain lesions. Prog Neuropsychopharmacol 19: 171–186
Ohara T, Tanaka K, Fukaya H, Demura N, Iimura A, Seno N (1997) SDZ ENA 713 facilitates central cholinergic functions and ameliorates spatial memory impairment in rats. Behav Brain Res 83: 229–233
Siek GC, Katz LS, Fishman EB, Korosi TS, Marquis JK (1990) Molecular forms of acetylcholinesterase in subcortical areas of normal and demented (Alzheimer-typ) patients. Biol Psychiatry 27: 573–580
Sussmann JL, Harel M, Frowlow F, Oefner C, Toker L, Silman I (1991) Atomic structure of aceylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253: 872–879
Tanaka K, Ogawa N, Asanuma M, Kondo Y, Mori A (1994) Chronic administration of acetylcholinesterase inhibitor in the senescent rat brain. Neurobiol Aging 15: 721–725
Whitehouse PJ (1993) Cholinergic therapy in dementia. Acta Neurol Scand [Suppl] 149: 42–45
Literatur
Anand R, Gharabawi G (1996) Clinical development of Exelon® (Ena 713): the Adena programme. J Drug Dev Clin Pract 8: 9–14
Anand R, Gharabawi G, Enz A (1996) Efficacy and safety results of the early phase studies with Exelon® (ENA 713) in Alzheimer’s disease: an overview. J Drug Dev Clin Pract 8: 1–8
Corey-Bloom J, Anand R, Veach J (1998) A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65
DeJong R, Osterlund O, Roy G (1989) Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 11: 545–554
Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J (1993) Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Prog Brain Res 98: 431–438
Rosen W, Mohs R, Davis K (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141: 1356–1364
Rösler M, Anand R, Cicin-Sain A et al. (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Br Med J 318: 633–638
Weinstock M, Razin M, Chorev M, Enz A (1994) Pharmacological evaluation of phenylcarbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm [Suppl] 43: 219–225
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Wien
About this chapter
Cite this chapter
Enz, A., Rösler, M. (1999). Rivastigmin. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_67
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6400-6_67
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7315-2
Online ISBN: 978-3-7091-6400-6
eBook Packages: Springer Book Archive